183 related articles for article (PubMed ID: 33453658)
1. Identification of nanobodies against hepatocellular carcinoma marker glypican-3.
Wang W; Xu C; Wang H; Jiang C
Mol Immunol; 2021 Mar; 131():13-22. PubMed ID: 33453658
[TBL] [Abstract][Full Text] [Related]
2. Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma.
Xia L; Teng Q; Chen Q; Zhang F
Int J Nanomedicine; 2020; 15():2197-2205. PubMed ID: 32280214
[TBL] [Abstract][Full Text] [Related]
3. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
4. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
6. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
7. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
[TBL] [Abstract][Full Text] [Related]
8. Production and characterization of GPC3-N protein and its nanobody.
Lao Z; Li S; Liang J; Su J; Gong X; Cui X; Zhao S
Protein Expr Purif; 2022 Aug; 195-196():106094. PubMed ID: 35436616
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
10. The development of a Glypican-3-specific binding peptide using
Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X
Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851
[TBL] [Abstract][Full Text] [Related]
11. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
13. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
14. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
16. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3.
Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW
J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3: a new target for cancer immunotherapy.
Ho M; Kim H
Eur J Cancer; 2011 Feb; 47(3):333-8. PubMed ID: 21112773
[TBL] [Abstract][Full Text] [Related]
18. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells.
Qi XH; Wu D; Cui HX; Ma N; Su J; Wang YT; Jiang YH
Mol Med Rep; 2014 Dec; 10(6):3177-84. PubMed ID: 25270552
[TBL] [Abstract][Full Text] [Related]
19. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma.
Yu L; Huang N; Sun H; Yang X; Fu Y; Lang Q; Wang J; Ge L
J Immunother; 2021 Apr; 44(3):106-113. PubMed ID: 33239522
[TBL] [Abstract][Full Text] [Related]
20. Prediction and preliminary screening of HLA-A*0201-restricted epitope peptides of human GPC3.
Hu P; Wei Z; Li R; Wu D; Meng Z
Int J Immunogenet; 2016 Jun; 43(3):166-70. PubMed ID: 27102087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
